Catch up on the top radiology content of the past week.
|Articles|January 19, 2000
Scanis launches European office
Mammography CAD developer Scanis is gearing up its global efforts in preparation for the launch of its Mammex TR system. The Foster City, CA-based firm has established a European marketing office in Eindhoven, the Netherlands. The office will be led by
Advertisement
Mammography CAD developer Scanis is gearing up its global efforts in preparation for the launch of its Mammex TR system. The Foster City, CA-based firm has established a European marketing office in Eindhoven, the Netherlands. The office will be led by Theo Spangenberg, who has been named European marketing director.
Scanis expects Mammex TR will be available in Europe in the first quarter. The unit has completed preclinical evaluation at the Norris Comprehensive Cancer Center at the University of Southern California (SCAN Special Report, January 2000), and was also recently installed at the Klinik Hirslanden in Zurich, Switzerland, where it will undergo further evaluation. Mammex TR was developed jointly with the TRW Center for Medical Image Analysis (SCAN 10/15/97).
Advertisement
Related to this article
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Magnetic resonance imaging offered a 29 percent higher sensitivity than CT for differentiating liver metastases, but CT provided 12 percent higher sensitivity than MRI for assessing vascular invasion, according to a new 40-study meta-analysis.
In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.
Does fractional flow reserve (FFR) or quantitative plaque burden from CCTA provide greater prognostic insight into coronary disease?
In the first of a three-part podcast episode, Wendie Berg, MD, PhD, FACR, FSBI, Manisha Bahl, MD, and Amy Patel, MD share insights on the utility of AI in breast imaging with respect to potential advantages, current concerns and future directions.
Catch up on the most-well viewed radiology content in September 2026.
The BiPASS program, which combines 68Ga PSMA PET imaging with prostate MRI prior to the use of prostate biopsy, is slated to be evaluated in an impending phase 3 trial.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Emerging Research Insights and New Advances in Neuroradiology
2
MRI, CT or Ultrasound: Which Modality Offers the Most Utility for Imaging of Pancreatic Cancer?
3
FDA Grants Fast Track Designation for Pre-Biopsy Use of PSMA PET and MRI for Prostate Cancer Detection
4
ASTRO: What New Phase 3 Research Reveals About SBRT for Patients with Localized Prostate Cancer
5